Abstract | BACKGROUND: SCOPE: In this review, we briefly describe (1) the role of pancreatic islet dysfunction in the onset and progression of T2DM, (2) the rationale for developing drugs that enhance incretin activity, (3) the evidence that inhibition of DPP-4 is effective in ameliorating islet dysfunction and improving glycemic control in T2DM, (4) the efficacy, safety, and tolerability of DPP-4 inhibitors as monotherapy and in combination with other antidiabetic agents, and (5) the potential utility of DPP-4 inhibitors relative to existing oral antidiabetic agents and newer antidiabetic drugs in the pipeline. The review is based upon MEDLINE literature searches (1966-August 2006) and abstracts and presentations from the American Diabetes Association Scientific Sessions (2002-2006) and the European Association for the Study of Diabetes Annual Meetings (1998-2006). Basic science, preclinical, and clinical studies and review articles published in the English language were evaluated and selected based upon consideration of their originality, relevance, and frequency of citation. FINDINGS:
DPP-4 inhibitors are a new class of antidiabetogenic drugs that provide comparable efficacy to current treatments. They are effective as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. The DPP-4 inhibitors are well tolerated, carry a low risk of producing hypoglycemia, and are weight neutral. The long-term durability of effect on glycemic control and beta-cell morphology and function remain to be established. CONCLUSIONS:
|
Authors | Richard E Pratley, Afshin Salsali |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 23
Issue 4
Pg. 919-31
(Apr 2007)
ISSN: 1473-4877 [Electronic] England |
PMID | 17407649
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Adenosine Deaminase Inhibitors
- Blood Glucose
- Dipeptidyl-Peptidase IV Inhibitors
- Glycoproteins
- Hypoglycemic Agents
- Nitriles
- Pyrazines
- Pyrrolidines
- Triazoles
- Gastric Inhibitory Polypeptide
- Glucagon-Like Peptide 1
- DPP4 protein, human
- Dipeptidyl Peptidase 4
- Vildagliptin
- Glucose
- Adamantane
- Sitagliptin Phosphate
|
Topics |
- Adamantane
(administration & dosage, analogs & derivatives)
- Adenosine Deaminase Inhibitors
- Animals
- Blood Glucose
(analysis)
- Diabetes Mellitus, Type 2
(drug therapy, pathology)
- Dipeptidyl Peptidase 4
- Dipeptidyl-Peptidase IV Inhibitors
- Drug Therapy, Combination
- Gastric Inhibitory Polypeptide
(pharmacology, physiology)
- Glucagon-Like Peptide 1
(antagonists & inhibitors, pharmacology, physiology)
- Glucose
(metabolism)
- Glycoproteins
(antagonists & inhibitors)
- Homeostasis
- Humans
- Hypoglycemic Agents
(adverse effects, therapeutic use)
- Islets of Langerhans
(drug effects, pathology, physiology)
- Models, Biological
- Nitriles
- Pyrazines
(administration & dosage)
- Pyrrolidines
- Sitagliptin Phosphate
- Triazoles
(administration & dosage)
- Vildagliptin
|